Patients with a KRAS A146–mutated tumor have a significantly higher absolute and relative TTV (median TTV of 672 cm3 and 24.5% of total liver volume) compared with patients with a KRAS G12 mutation (median TTV of 74 cm3 and 4.1% of total liver volume; P = .036 and P = .053, respectively) and G13 mutation (median TTV of 55 cm3 and 3.5% of total liver volume; P = .021 and P = .026, respectively). Here, KRAS is linked to neoplasm.